Hey there, bargain hunter.
While everyone was arguing about tariffs and trade war noise in April 2026, a quiet but important signal fired underneath the surface. ASML reported Q1 2026 bookings of 3.94 billion euros, smashing the 3.6 billion euro consensus. Lam Research guided Q2 revenue to $4.9 billion, well above the $4.6 billion estimate. KLA raised its full-year outlook for the second consecutive quarter. These are not coincidences – they are a coordinated signal that the wafer fabrication equipment cycle is in early-to-mid acceleration, not late stage.
The Scoreboard
- ASML Q1 bookings: 3.94B euros vs. 3.6B estimate – 9% beat
- Lam Research Q2 guide: $4.9B revenue, 6.5% above street
- KLA full-year EPS guide raised: now $32.50 to $35.50 vs. prior $30.00 to $33.00
- ASML forward P/E: approximately 24x – a 30% discount to its 2024 peak multiple
- Lam Research forward P/E: approximately 19x with 20%-plus EPS growth projected
Why This Cycle Is Different
Prior upcycles were driven almost entirely by memory and consumer logic. This one has three separate demand engines running simultaneously: AI accelerator buildout requiring advanced logic nodes, sovereign chip programs in Europe, Japan, and India funding new fab construction, and a US CHIPS Act-funded domestic capacity wave that is just beginning to place equipment orders.
ASML’s EUV backlog now stretches into 2028. That is not a cycle – that is a structural multi-year demand floor.
The Cheap Investor Scorecard
- Book-to-bill ratio above 1.0 across major equipment names: Yes
- Gross margin expansion trend: Yes for ASML and KLA
- Valuation at discount to 5-year average multiple: Yes, meaningfully so
- Multiple sovereign fab programs actively spending: Yes
- AI capex from hyperscalers still guiding higher: Yes – Microsoft, Google, Meta all raised 2026 capex
Bottom Line
The semiconductor equipment names are priced for a slowdown that the bookings data flatly contradict. If ASML bookings hold above 3.5 billion euros per quarter and Lam delivers on its Q2 guide, these stocks have 25% to 35% upside to fair value over 12 to 18 months. Start a position in ASML or LRCX on any macro-driven pullback and add on confirmation of Q2 delivery numbers. The cycle is your friend here – do not let tariff headlines talk you out of it.
